Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Dexcom (DXCM) Shares Outstanding (2016 - 2026)

Dexcom has reported Shares Outstanding over the past 17 years, most recently at $385.9 million for Q1 2026.

  • Quarterly Shares Outstanding fell 1.58% to $385.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $385.9 million through Mar 2026, down 1.58% year-over-year, with the annual reading at $384.8 million for FY2025, 1.51% down from the prior year.
  • Shares Outstanding was $385.9 million for Q1 2026 at Dexcom, roughly flat from $384.8 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $400.7 million in Q2 2024 and troughed at $384.8 million in Q4 2025.
  • The 5-year median for Shares Outstanding is $390.0 million (2025), against an average of $389.8 million.
  • Year-over-year, Shares Outstanding soared 306.0% in 2022 and then fell 2.12% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $386.3 million in 2022, then decreased by 0.23% to $385.4 million in 2023, then grew by 1.38% to $390.7 million in 2024, then fell by 1.51% to $384.8 million in 2025, then grew by 0.29% to $385.9 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Shares Outstanding are $385.9 million (Q1 2026), $384.8 million (Q4 2025), and $390.0 million (Q3 2025).